

Special Issue

Adipose Tissue in Health and Diseases

Message from the Guest Editors

Adipose tissue (AT) is a highly complex metabolic organ that plays a role in regulating many aspects of whole-body physiology, including food intake, energy balance, insulin sensitivity, body temperature, and immune responses. Adipose tissue is highly heterogeneous. Heterogeneous AT is not solely composed of mature adipocytes, but is additionally comprised of adipocyte precursors/stem cells, immune cells, blood cells, and lymphatic capillaries consisting of endothelial cells (ECs). Each anatomical fat depot differs in metabolic and hormonal profiles and has distinct physiological roles. The differential accumulation of specific depots therefore translates into different clinical outcomes. This Special Issue on "Adipose Tissue in Health and Disease" aims to provide up-to-date insight into the remarkable complexity of the adipose tissue heterogeneity and metabolism, while also casting a light on its dysregulation in the context of many different human diseases. These run the gamut from obesity and type two diabetes to the rare adipose tissue disorders, including multiple symmetric lipomatosis (MSL), lipedema and Dercum's disease (DD).

Guest Editors

Dr. Atefeh Rabiee

Department of Physiology & Pharmacology, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA

Dr. Ewa Bielszyk-Maczyńska

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/154799

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).